GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beximco Pharmaceuticals Ltd (FRA:R2WA) » Definitions » Research & Development

Beximco Pharmaceuticals (FRA:R2WA) Research & Development : €0.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Beximco Pharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Beximco Pharmaceuticals's Research & Development for the three months ended in Dec. 2024 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was €0.0 Mil.


Beximco Pharmaceuticals Research & Development Historical Data

The historical data trend for Beximco Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beximco Pharmaceuticals Research & Development Chart

Beximco Pharmaceuticals Annual Data
Trend Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.05 0.05 0.02 0.02

Beximco Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Beximco Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beximco Pharmaceuticals  (FRA:R2WA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Beximco Pharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of Beximco Pharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Beximco Pharmaceuticals Business Description

Traded in Other Exchanges
Address
19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.

Beximco Pharmaceuticals Headlines

No Headlines